Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rapport Therapeutics (RAPP) Net Income towards Common Stockholders (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Net Income towards Common Stockholders data on record, last reported at -$19.9 million in Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 17.48% to -$19.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$107.3 million, a 34.6% decrease, with the full-year FY2025 number at -$111.5 million, down 42.37% from a year prior.
  • Net Income towards Common Stockholders reached -$19.9 million in Q1 2026 per RAPP's latest filing, up from -$33.8 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for RAPP hit a ceiling of -$6.4 million in Q2 2023 and a floor of -$33.8 million in Q4 2025.
  • A 4-year average of -$19.9 million and a median of -$19.9 million in 2024 define the central range for Net Income towards Common Stockholders.
  • Peak YoY movement for Net Income towards Common Stockholders: plummeted 182.65% in 2024, then rose 17.48% in 2026.
  • Tracing RAPP's Net Income towards Common Stockholders over 4 years: stood at -$13.5 million in 2023, then tumbled by 47.79% to -$20.0 million in 2024, then tumbled by 68.98% to -$33.8 million in 2025, then skyrocketed by 41.19% to -$19.9 million in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for RAPP at -$19.9 million in Q1 2026, -$33.8 million in Q4 2025, and -$26.9 million in Q3 2025.